Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., announced on September 4, 2025, the completion of Phase II of its AI Development Program with strategic partner Yuva Biosciences, Inc. This phase focused on identifying small molecule candidates for mitochondrial health.
As part of Phase II, YuvaBio delivered to Northstrive a shortlist of small molecule candidates believed to have the potential to promote mitochondrial health to combat obesity and cardiac diseases. YuvaBio compiled these compounds from 12 curated libraries, aligning with Northstrive Bio’s therapeutic focus.
MitoNova™, YuvaBio’s AI platform, screened the chemical space to evaluate predicted impact on muscle preservation and metabolic health. Northstrive now has the opportunity to review this shortlist of compounds and analyze their potential for advancement to experimental testing and clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.